Phase 2 trial of a novel tuberculosis drug launched

During the Union World Conference on Lung Health 2023, held in Paris, France, on Nov 15–18, results from preclinical studies and a phase 1 trial of a novel candidate tuberculosis drug were presented. The new compound, named TBAJ-876, belongs to the diarylquinoline class of antibiotics (like bedaquiline).